laboratory specialized in the treatment of rare neurological diseases
  • [Corporate] Home Banner

About Theranexus

Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells.

Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

THERANEXUS and BBDF present progress on the Batten-1 program at the Translational Research Conference for the Management OF NCLs on 3 and 4 November, 2022 in Chicago

02/11/2022

Download PDF File(<1Mo)

Theranexus and inserm TRANSFERT sign a strategic alliance to identify advanced therapy drug candidates for rare neurological diseases

20/10/2022

Download PDF File(<1Mo)

THERANEXUS announces its financial result for the first half of 2022

27/09/2022

Download PDF File(<1Mo)

THERANEXUS and BBDF finalize recruitment for phase I/II trial to evaluate Batten-1 in Batten disease

08/09/2022

Download PDF File(412Ko)

Theranexus publishes its cash position as of 30 June 2022

12/07/2022

Download PDF File(253Ko)